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Background: Individually submitted prostatic needle biopsies are recommended by most guidelines because of
their potential advantage in terms of core quality. However, unspecified bilateral biopsies are commonly submitted
in many centers. The length of the core is the key quality indicator of prostate biopsies. Because there are few
recent publications comparing the quality of 12 site-designated biopsies versus pooled biopsies, we compared the
lengths of the biopsies obtained by both methods.
Methods: The material was obtained from 471 consecutive subjects who underwent prostatic needle biopsy in the
Tampere University Hospital district between January and June 2013. Biopsies from 344 subjects fulfilled the
inclusion criteria. The total number of cores obtained was 4047. The core lengths were measured on microscope
slides. Extraprostatic tissue was subtracted from the core length.
Results: The aggregate lengths observed were 129.5 ± 21.8 mm (mean ± SD) for site-designated cores and
136.9 ± 26.4 mm for pooled cores (p = 0.09). The length of the core was 10.8 ± 1.8 mm for site-designated cores
and 11.4 ± 2.2 mm for pooled cores (p = 0.87). The median length for pooled cores was 11 mm (range 5 mm – 18 mm).
For individual site-designated cores, the median length was 11 mm (range 7 mm −15 mm). The core length was
not correlated with the number of cores embedded into one paraffin block (r = 0.015). There was no significant
difference in cancer detection rate (p = 0.62).
Conclusions: Our results suggest that unspecified bilateral biopsies do not automatically lead to reduced core length.
We conclude that carefully embedded multiple (three to nine) cores per block may yield cores of equal quality in a
more cost-efficient way and that current guidelines favoring individually submitted cores may be too strict.
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The diagnosis of prostatic adenocarcinoma is based on
the histopathological findings obtained from prostatic
needle biopsies. There is a lot of debate on the best
protocol for submitting and labeling of prostate biopsies.
According to several current guidelines, individual site-
designated biopsies submitted in separate vials are pre-
ferred, as they are thought to give better quality samples* Correspondence: teemu.tolonen@fimlab.fi
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unless otherwise stated.in terms of tissue fragmentation as well as core length
[1,2]. However, it is a common practice to submit
unspecified bilateral biopsies both in the U.S. and in
Europe [3,4]. The length of the biopsy core is the key
quality indicator of a successful biopsy, which influences
cancer detection rates and the estimation of prognostic
parameters [5-7]. Currently, the recommended proced-
ure is to take five to six biopsies from each side [1,2].
Specifically, additional laterally targeted biopsies have
been shown to detect 31% more cancers when compared
to the sextant biopsy protocol [5]. The role of aug-
mented biopsy protocols is still controversial. It has been
suggested that there is no advantage to taking extendedl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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biopsy [8,9]. However, a recent meta-analysis has shown
that initial diagnostic saturation biopsies may be war-
ranted for patients with low PSA-values or high-volume
prostates [10].
In terms of biopsy quality, it has been suggested that
up to three cores could be safely embedded in one paraf-
fin block without compromising the biopsy quality [11].
Currently, approximately half of the pathology laborator-
ies in Europe receive unspecified bilateral biopsies to-
gether with individually submitted targeted biopsies
from a distinct nodule, while only 40% of laboratories
receive all biopsies in separate vials [4]. In the U.S., it is
slightly more common to submit site-designated biopsies
[3]. Compared to pooled biopsies, a submission of 12
site-designated biopsy cores by the urologist increases
the workload for pathology laboratories. The advantage
of site-designated biopsies is that localization informa-
tion is spared, which is important for active surveillance
follow-up protocols and helps the urologist to plan
surgeries. The quality of needle biopsies is operator
dependent, but the main result (i.e., how the tissue looks
on a slide) is also dependent upon the pathology labora-
tory [12]. A recent guideline by the pathology committee
of the European Randomized Study of Screening for
Prostate Cancer (ERSPC) highlights the importance of
special techniques in processing and (pre-)embedding
for preserving the quality of the biopsy [13]. Such tech-
niques include the use of sponges to flatten the cores
during fixation and dehydration, and the use of metal
tampers for the embedding process.
The aim of this study was to determine whether there
is a quality difference between site-designated individu-
ally embedded and unspecified bilateral (pooled)
biopsies, using core length as the main quality indicator
and cancer detection rate as a secondary measure. It was
hypothesized, that pooling samples in the same biopsy
container and resulting paraffin block does not affect the
quality of the biopsy. Pooling biopsies reduces the work-
load of laboratory technicians and pathologists, so if
pooled samples are of similar quality than site-
designated biopsies, it would be possible to get the same
results with less effort.
Methods
The study was approved by the Ethical Committee of
Tampere University Hospital (TAUH), reference number
R03203. The material was obtained from 471 consecu-
tive prostate biopsies submitted to Fimlab Laboratories
for evaluation during a half year period from January to
June 2013. The biopsies were taken in the Tampere
University Hospital (TAUH) district by several urologists
under standard operating procedure. All the obtained
prostate biopsies were evaluated with the followinginclusion criteria: 1) the biopsy was reported by one of
our five uropathologists (ML, MT, SH, PK, TT), 2) the
biopsies were comprised of either 12 individually sub-
mitted cores or bilateral pooled biopsies submitted in
two formalin vials (plus an extra vial containing one core
from a distinct nodule in some cases), and 3) all cores
were measured in millimeters and reported in a stan-
dardized manner (see later section). Biopsies from 344
subjects fulfilled the inclusion criteria and yielded a total
number of 4047 biopsy cores. All of the accepted site-
designated biopsies consisted of a set of 12 biopsy con-
tainers with a single biopsy inside, except for one case in
which only 11 containers were submitted because there
were erroneously two biopsies in one vial. A total of 127
cases were excluded. Although it met the inclusion cri-
teria, one case with 12 individually processed cores con-
taining only 20 mm intraprostatic tissue was excluded as
a statistical outlier. The inclusion procedure is presented
schematically in Figure 1.
All biopsies were taken transrectally with ultrasonog-
raphy guidance using an 18-gauge needle biopsy gun
with an 18-mm sample notch (Bard peripheral vascular,
Temple, AZ, U.S.A., ref no. MC 1825) and a side-fire
probe. Biopsies were put into vials containing 10%
neutral-buffered formalin straight from the biopsy nee-
dle. Biopsies from a single patient were transported to
our laboratory either in 12 separate vials or in two vials
containing several biopsy cores (median number of cores
per container was six). The number of submitted vials
depended on how the urologist performed the prostate bi-
opsy. All biopsies were processed in Fimlab Laboratories,
Tampere University Hospital, in Tampere, Finland.
Site-designated individual biopsies were transferred to
separate tissue cassettes in which they were straightened
(not stretched) and flattened between sponges during
standard dehydration and microwave processing. Pooled
biopsies from one vial were treated equally but remained
pooled (e.g., multiple straightened cores were sand-
wiched between sponges into one cassette). Two to four
sections were cut from the individual cores and trans-
ferred to one slide, depending on the technologist’s vis-
ual impression. Because pooled biopsies may have more
planar variation inside the paraffin blocks, they were cut
on four levels which resulted in the generation of two
slides. The blocks were not cut through and step sec-
tions were not collected because our current protocol
offers residual material for potential immunostaining in
most cases.
The lengths of the biopsy cores were collected from
pathology reports. For individually processed biopsies,
the lengths were reported for each biopsy core in
millimeters. The 12 loci of individual biopsies were stan-
dardized as follows: 1–3 were right lateral base, mid and
apex, 4–6 were right medial base, mid and apex, 7–9
Figure 1 Study flow chart. The inclusion criteria were as follows: 1. the biopsy was reported by an uropathologist, 2. bilateral pooled biopsies in
two formalin vials or 12 individually submitted cores, 3. the core lengths were measured and reported in millimeters in a standardized manner.
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medial base, mid and apex, respectively. The current
scheme for site-specific needle biopsies in the TAUH
district is presented in Figure 2. In the case of multiple
biopsies per paraffin block, the information regarding
the number of biopsies in the block and the total length
of the biopsies in millimeters was required. Separately
submitted additional cores targeting a region of palpable
resistance were excluded from the length measurements
but were included in the cancer detection rate. The
length of the core and the possible length of the cancer-
ous tissue were measured from hematoxylin-eosin
(H&E) -stained slides either under a light microscope as
multiples of 4x/10x objectives visual field diameter or by
a liner, depending on the extent of the cancer. According
to our standardized protocol, extraprostatic tissue was
subtracted from the total core length to obtain the mostFigure 2 Biopsy protocol for 12 individually submitted
site-designated biopsy cores.accurate percentage of cancer. Tissue was considered
extraprostatic when containing obvious fat or loose mes-
enchymal tissue that was distinct from the (pseudo)cap-
sule. For cancerous prostates, a standardized scoring
table was applied. The recorded parameters included
primary and secondary Gleason patterns, the number of
positive cores/total number of cores, cancer length/total
length, the percentage of cancer, high grade prostatic
intraepithelial neoplasia, and perineural invasion. The
microscopic appearance of slides with individually em-
bedded and pooled biopsies are represented in Figure 3.Statistical analysis
Data were analyzed using a two-tailed Wilcoxon-Mann–
Whitney test to compare aggregate and single biopsy
length means and a two-tailed Fisher’s exact test to com-
pare cancer detection rates. The impact of the number
of cores embedded in a single paraffin block on the
mean length of cores in the corresponding block was
tested using Pearson’s correlation coefficient analysis.
Statistical significance was considered at p < 0.05.Results
Individual site-designated biopsies were submitted to
our laboratory in 57 (16.6%) cases, and non-specified
(pooled) bilateral biopsies were submitted in 287 (83.4%)
cases. Of the pooled biopsies, exactly six plus six cores
from the right and left sides were obtained 188 (65.5%)
times. More than 12 biopsies were submitted in 38
(13.2%) cases, and less than 10 biopsies were submitted
in 18 (6.2%) cases. The minimum number of biopsy
cores per subject was 6 (n = 1), and the maximum num-
ber was 15 (n = 7).
Figure 3 Two H&E-stained microscopy slides illustrating the
visual appearance of individually embedded and pooled biopsies.
On the left: individual biopsy core sectioned at three levels. On the
right: six biopsy cores embedded into one paraffin block and sectioned
at two levels.
Table 2 The impact of the number of biopsy cores
embedded into one paraffin block to the mean length of
cores in the corresponding block1
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one subject was 133.6 ± 29.9 mm (mean ± SD). No
statistically significant difference in the mean aggregate
lengths was noted between site-designated and pooled
(6 + 6) biopsies or between benign and malignant
biopsies (Table 1).
The average core length was 11.4 ± 2.2 mm for pooled
biopsies and 10.8 ± 1.8 mm for individually processed
cores (p = 0.87). The median length for pooled cores was
11 mm (range 5 mm - 18 mm). For individual site-
designated cores the median length was 11 mm (range
7 mm - 15 mm). Because the number of biopsy cores in
the vials varied from 1 to 9, we also tested whether
increasing the number of cores in a paraffin block would
have an adverse effect on the mean length of the coresTable 1 Comparison of aggregate lengths of the biopsy
cores
n Aggregate length, mm (mean ± SD)
All 344 133.6 ± 29.9
Site-designated 57 129.5 ± 21.81
Pooled 6 + 6 188 136.9 ± 26.41
Benign 151 132.7 ± 29.32
Malignant 193 134.2 ± 30.42
1No statistically significant difference was noted between 12 site-designated
cores and unspecified bilateral (6 + 6) cores, p = 0.09.
2No statistically significant difference was noted between benign and
malignant cases, p = 0.25.as one might expect. However, no correlation was
noted (Table 2).
The overall cancer detection rate was 55.8%.
Adenocarcinoma was detected in 28/57 (49.1%) cases with
site-designated biopsies and in 164/287 (57.1%) cases with
pooled biopsies (p = 0.62).Discussion
A recent survey regarding the handling of prostate biop-
sies by the European Network for Uropathologists
(ENUP) showed that there is a wide diversity among
European pathology centers in the handling of prostate
biopsy specimens [4]. The number of biopsy cores taken,
the number of cores in a formalin vial, and the (pre-)em-
bedding methods are all variable. Multiple biopsies per
vial (and paraffin block) were used in approximately half
of the centers that participated in the survey, which is
not recommended due to a presumption that tissue
quality will be compromised. In our study, there was no
difference in the lengths of biopsies regardless of
whether they were processed individually or pooled. Fur-
thermore, cancer detection rates were approximately
equal between the groups. The slightly lower cancer de-
tection rate noted in individually processed biopsies may
be related to the different indications for a biopsy pro-
cedure between the groups. However, the observed
overall cancer detection rate of 55.8% is quite high.
Previously, in a Finnish prostate cancer screening study
conducted as a part of the European Randomized Study
of Screening for Prostate Cancer (ERSPC), the observed
cancer detection rate at a PSA cutoff level of 4 μg/l was
found to be 27% [14].
There are several possible reasons for the high cancer
detection rate observed in this study. The population
included in the study has a relatively high PSA screening
frequency due to the prostate cancer screening trial.No. of cores in
paraffin block
n Length of cores, mm (mean ± SD)
1 684 10.8 ± 1.8
3 8 12.9 ± 2.1
4 20 10.6 ± 2.7
5 75 11.0 ± 2.9
6 417 11.5 ± 2.4
7 40 11.8 ± 2.5
8 10 11.5 ± 2.1
9 2 11.1 ± 1.2
1The length of biopsies was not correlated to the number of cores in the
block, r = 0.015.
Figure 4 Two complete slide sets illustrating the different
workload of site-designated and pooled biopsies. Individual
biopsy cores yield twelve slides per subject whereas pooled biopsies
yield only four slides.
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the start of screening trial in 1996, which has lead to a
higher threshold for taking biopsies. Also, the PSA value
is no longer considered the only indication for taking a
prostate biopsy; more significance is given to the value
of free PSA per total PSA. Another reason for the high
cancer detection rate may be that some of biopsies are
taken from patients in an active follow-up. Finally, there
might be skewness in the results due to the inclusion
criteria. Benign biopsies are not always reported with the
same accuracy as cancer cases, and this inaccuracy in
reporting of biopsy length may have disqualified some
benign cases from inclusion in this study. Also, urgent
cases with a high suspicion of cancer are more likely to
be reported by one of the uropathologists conducting
the study, which may increase the overall cancer
detection percentage.
Our results suggest that the problems encountered
with multiple biopsies in one container can be overcome
by special tissue pre-embedding methods, including
straightening and flattening the cores between sponges
before tissue processing and by paying attention to the
laboratory technologist’s education. According to the
ERSPC pathology committee’s newest guidelines, up to
three cores can be safely embedded in a single paraffin
block without significant tissue loss [13]. Our results
suggest that the maximum number of cores that can
safely be embedded in a single paraffin block may be a
matter of technique – if one is able to embed single
cores well enough, why would it not work for the core
next to it? In fact, in one of our earlier experiments, we
embedded twelve biopsies in one paraffin block and
obtained a satisfactory visual appearance. However, the
technique was abandoned because there were two obvi-
ous disadvantages: the orientation of the biopsies in the
paraffin block needed to be diagonal instead of longitu-
dinal which made sectioning more difficult, and the tips
of the cores stayed outside of the staining area of the
automated immunostaining system due to their mar-
ginal position.
According to Bostwick et al., the mean length of
prostate biopsies in Western Europe was 13.1 mm at
the entry level of their study [12]. In the present study,
the mean length of the core was shorter (11.4 mm).
However, the aforementioned values are not compar-
able because in our study extraprostatic tissue was
subtracted to obtain the most accurate percentage of
cancer tissue possible.
It is likely that the most important advantage of indi-
vidually embedded biopsies is not the biopsy core quality
but rather the spared locus information. This is an im-
portant issue in selected cases, and site-designated biop-
sies should be encouraged. On the other hand, the use
of multiple biopsies per vial (and paraffin block) issupported by less extensive laboratory loading and better
facilities for immunohistochemistry. Our medium-sized
laboratory receives biopsies from approximately 1000
patients per year. Widespread use of site-designated
biopsies would annually increase the number of paraffin
blocks by approximately 10,000, which increases the
workload for the pathology laboratory throughout vari-
ous steps including processing, embedding, sectioning
and analyzing. Roughly estimated this would take ap-
proximately 80 working days for sectioning only and
would increase the time pathologists spend analyzing
and reporting prostate biopsies (Figure 4).
There are several limitations in the present study.
First, the prostate biopsies, although taken with same
equipment, may have variations due to different
urologists who performed the biopsies. Second, the
slides were not re-evaluated. Additionally, by digitizing
all of the material and measuring core areas instead of
the lengths of the biopsies, the quality indicator would
have been more accurate. In the present study we pre-
ferred to use our current methods because at the mo-
ment there are no area-based prognostic nomograms
available, and measuring the actual tissue from histo-
logical slides is the gold standard. Third, the subtraction
of extraprostatic tissue is somewhat subjective. However,
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types of specimens. Finally, the amount of site-
designated individual biopsies only represented 17% of
the studied cases and the imbalance between the groups
may cause unreliability in the final results. As a limita-
tion of this study, it must be pointed out, that this study
only shows the situation in our facility and to determine
the real impact in a clinical context, a multicenter study
would describe the overall situation of prostate biopsies
better. Our aim was simply to determine whether there
were fundamental differences in favor of either method.
Conclusions
The number of submitted vials depends on how the ur-
ologist performs the prostate biopsy. We have received
both individually submitted and pooled biopsies for
several years without noticing an obvious difference in
their quality. However, the workload for laboratory tech-
nologists and pathologists is substantially higher for site-
designated individually embedded biopsy cores. In our
material, we did not find evidence regarding the superior
quality of the individually submitted and embedded
biopsies. We conclude that the current recommendations
favoring site-designated biopsies may be too strict - the
guidelines should probably recommend a result rather
than a process.
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